Multicomponent Macrocyclic IL-17a Modifier

[Image: see text] IL-17a is a major inflammation target, with several approved antibodies in clinical use. Small-molecule IL-17a antagonists are an emerging hot topic, with the recent advancement of three compounds into clinical trials. Here, we describe the design, discovery, synthesis, and screeni...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelraheem, Eman, Lubberink, Max, Wang, Wenja, Li, Jingyao, Reyes Romero, Atilio, van der Straat, Robin, Du, Xiaochen, Groves, Matthew, Dömling, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465830/
https://www.ncbi.nlm.nih.gov/pubmed/36105327
http://dx.doi.org/10.1021/acsmedchemlett.2c00257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465830/
https://www.ncbi.nlm.nih.gov/pubmed/36105327
http://dx.doi.org/10.1021/acsmedchemlett.2c00257

Ejemplares similares